Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SAN

Sanofi (SAN)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:EU:SAN
DateTimeSourceHeadlineSymbolCompany
31/05/202420:00GlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
31/05/202420:00GlobeNewswire Inc.Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salariéEU:SANSanofi
31/05/202420:00GlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
31/05/202415:05GlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
31/05/202415:00GlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
31/05/202415:00GlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
31/05/202415:00GlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
30/05/202423:01GlobeNewswire Inc.Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.EU:SANSanofi
30/05/202423:01GlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
30/05/202423:01GlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
27/05/202415:00GlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
27/05/202415:00GlobeNewswire Inc.Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantationEU:SANSanofi
27/05/202415:00GlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
21/05/202415:30GlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
21/05/202415:30GlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
21/05/202415:30GlobeNewswire Inc.Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IAEU:SANSanofi
21/05/202406:54GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024EU:SANSanofi
21/05/202406:54GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - April 2024EU:SANSanofi
21/05/202404:15GlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
21/05/202404:15GlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
21/05/202404:15GlobeNewswire Inc.Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCOEU:SANSanofi
13/05/202415:00GlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireEU:SANSanofi
13/05/202415:00GlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyEU:SANSanofi
13/05/202415:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)EU:SANSanofi
10/05/202416:00GlobeNewswire Inc.Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19EU:SANSanofi
10/05/202416:00GlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
10/05/202416:00GlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Your Recent History

Delayed Upgrade Clock